Gilbert G.G. Donders

Real Life Data for Relugolix/Estradiol/Norethisteroneacetate Treatment for Chronic Pelvic Pain in Endometriosis Patients

Francesca Donders, Izabella Wojcik, Mohamed Akkouch, Mariam Zeyneddin et autres

Background/objective: Relugolix–estradiol–norethisterone acetate combination therapy (relugolix CT) was licensed for endometriosis-associated pain on the strength of two big randomized controlled trials, in which dysmenorrhea improved in 73–74% and non-cyclical pelvic pain in 58–60% of participants, with discontinuation for adverse events in about …

Accuracy of Allplex HPV HR Detection Full Genotyping Assay on Cervical Samples Compared to Vaginal Self‐Samples

Ardashel Latsuzbaia, Severien Van Keer, Davy Vanden Broeck, Steven Weyers et autres

Vaginal self-sampling is increasingly integrated into cervical cancer screening programs, requiring evidence of accurate HPV testing on self-collected samples. This study evaluated the clinical accuracy of Allplex HPV HR Detection (Allplex) within VALHUDES, a framework established to assess the clinical performance of …

be, de, nl (code pays fourni par la source)

Effect of elinzanetant on sleep disturbance and aspects of quality of life in women with breast cancer experiencing vasomotor symptoms: OASIS-4 subgroup analysis by type of endocrine therapy.

Cláudio Soares, Kaisa Laapas, Christian Seitz, Gilbert G.G. Donders et autres

512 Background: In the Phase III OASIS-4 trial, elinzanetant (EZN), a dual neurokinin (NK)-targeted therapy (NK-1 and NK-3 receptor antagonist), significantly improved vasomotor symptoms (VMS), sleep disturbance and menopause-related quality of life (QoL) in women taking endocrine therapy (ET) for breast cancer. …

ca, fi, de, gb, ch, fr (code pays fourni par la source)

Citizen science reveals comorbidities in endometriosis with no shift in vaginal microbiome composition

I Rahou, Thies Gehrmann, Sarah Ahannach, Camille Nina Allonsius et autres

Endometriosis is a chronic inflammatory condition affecting 2–10% of reproductive-aged women, most commonly presenting with pelvic pain and subfertility. While its impact on reproductive health is increasingly recognized, the vaginal microbiome’s role in the pathogenesis of endometriosis is still unclear and a …

be (code pays fourni par la source)

Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer

Severien Van Keer, Rianne van den Helder, Laura Téblick, Annemie De Smet et autres

BACKGROUND: DNA methylation analysis provides a promising triage strategy for cervical intraepithelial neoplasia (CIN) and cancer detection following Human Papillomavirus (HPV) testing on self-collected samples, including urine. METHODS: This study aimed to develop an entirely molecular cervical screening approach based on HPV …

Ouganda, nl, be, de (code pays fourni par la source)

Local albumin excess exacerbates Candida albicans-induced inflammasome activation linked with hyperinflammation during vulvovaginal candidiasis.

Mark Gresnigt, Sophie Austermeier, Axel Dietschmann, Gianluca Vascelli et autres

de, it, nl, us, fr, be (code pays fourni par la source)

The female intimate microbiome space

Leonore Vander Donck, Thies Gehrmann, Sarah Ahannach, Sarah Van den Bosch et autres

Despite its importance in health, the female intimate skin microbiome remains understudied. In this Isala study we explored microbial dispersal across intimate body sites, including the vagina, groins, breast and mouth. Microbial similarity correlated with physical proximity, suggesting dispersal influenced by hygiene …

be (code pays fourni par la source)

EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol

Eef van den Borst, Davy Vanden Broeck, Philippe De Sutter, Gilbert G.G. Donders et autres

OBJECTIVE: Human papillomavirus (HPV) testing on self-collected urine and vaginal samples has shown great potential for cervical cancer screening by offering a non-invasive and approachable alternative to un(der)screened populations. Although many HPV tests were validated on cervical samples, data regarding clinical performance …

be, Ouganda, de (code pays fourni par la source)

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Fátima Cardoso, Susanne Parke, Donal J. Brennan, Paula Briggs et autres

BACKGROUND: Women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking on the effects of elinzanetant, a neurokinin-targeted therapy shown to be effective in …

pt, de, ie, gb, be, ch, fi (code pays fourni par la source)

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.

Fátima Cardoso, Donal J. Brennan, Paula Briggs, Gilbert G.G. Donders et autres

508 Background: Vasomotor symptoms (VMS) associated with adjuvant endocrine therapy (AET) impact quality of life and decrease treatment adherence, worsening breast cancer outcomes. There are few effective treatment options and none approved for this indication. Methods: The 52-week randomized phase 3 trial …

ie, gb, ch, de, fi (code pays fourni par la source)

Impact of elinzanetant on sleep disturbances and quality of life in women undergoing adjuvant endocrine therapy for breast cancer: Phase 3 OASIS 4 trial.

Donal J. Brennan, Fátima Cardoso, Paula Briggs, Gilbert G.G. Donders et autres

12063 Background: Vasomotor symptoms (VMS) and sleep disturbances are common in women taking adjuvant endocrine therapy (AET) for hormone receptor-positive (HR+) breast cancer and can impact quality of life and treatment adherence, potentially affecting breast cancer outcomes. There are few efficacious treatments …

ie, gb, ch, de, fi (code pays fourni par la source)

Women’s perceptions and preferences toward HPV self-sampling in France: A questionnaire within the French CapU4 Trial

Hélène De Pauw, Alexandra Ducancelle, Marc Arbyn, Adeline Pivert et autres

BACKGROUND: Despite organised screening efforts since 2018 targeting under-screened women, cervical cancer (CC) screening coverage remains moderate (60 %) in France. The target age for HPV-based screening is women aged 30-65. Vaginal self-sampling (VSS) has recently been introduced for women who have …

be, fr (code pays fourni par la source)